7-羟基-2,3-二氢异吲哚-1-酮 | 1033809-85-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 中文名称: 7-羟基-2,3-二氢异吲哚-1-酮
• 中文别名: 2,3-二氢-7-羟基-1H-异吲哚-1-酮；7-羟基异吲哚啉-1-酮
• 英文名称: 7-hydroxyisoindolin-1-one
• 英文别名: 7-hydroxy-2,3-dihydro-1H-isoindol-1-one；7-hydroxy-2,3-dihydroisoindol-1-one
• CAS: 1033809-85-6
• 化学式: C₈H₇NO₂
• mdl: MFCD18416894
• 分子量: 149.149
• InChiKey: QZKWUFXTQKCDBI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933790090

反应信息

• 作为反应物：
  描述：

  7-羟基-2,3-二氢异吲哚-1-酮 在 platinum on carbon 、 氢气 、 potassium carbonate 作用下， 以 四氢呋喃 、 甲醇 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 32.0h， 生成 7-(4-amino-2-chlorophenoxy)-2,3-dihydro-1H-isoindol-1-one
  参考文献：
  名称：

  Design and Synthesis of Pyrrolo[3,2-d]pyrimidine Human Epidermal Growth Factor Receptor 2 (HER2)/Epidermal Growth Factor Receptor (EGFR) Dual Inhibitors: Exploration of Novel Back-Pocket Binders

  摘要：

  To develop novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) kinase inhibitors, we explored pyrrolo[3,2-d]pyrimidine derivatives bearing bicyclic fused rings designed to fit the back pocket of the HER2/EGFR proteins. Among them, the 1,2-benzisothiazole (42m) ring was selected as a suitable back pocket binder because of its potent HER2/EGFR binding and cell growth inhibitory (GI) activities and pseudoirreversibility (PI) profile as well as good bioavailability (BA). Ultimately, we arrived at our preclinical candidate 51m by optimization of the N-5 side chain to improve CYP inhibition and metabolic stability profiles without a loss of potency (HER2/EGFR inhibitory activity, IC50, 0.98/2.5 nM; and GI activity BT-474 cells, GI(50), 2.0 nM). Reflecting the strong in vitro activities, 51m exhibited potent tumor regressive efficacy against both HER2- and EGFR-overexpressing tumor (4-1ST and CAL27) xenograft models in mice at oral doses of 50 mg/kg and 100 mg/kg.

  DOI：

  10.1021/jm300185p
• 作为产物：
  描述：

  4-溴-7-羟基异吲哚啉-1-酮 在 钯 氮气 、 氢气 、 钯 作用下， 以 甲醇 为溶剂， 反应 2.0h， 以to give the title compound (149 mg) as a yellow powder的产率得到7-羟基-2,3-二氢异吲哚-1-酮
  参考文献：
  名称：

  FUSED HETEROCYCLIC COMPOUND

  摘要：

  本发明提供了一种具有酪氨酸激酶抑制作用的融合杂环化合物，其表示为以下式子：其中，R1是氢原子、卤素原子或通过碳原子、氮原子或氧原子键合的可选取代基团；R2是氢原子或通过碳原子或硫原子键合的可选取代基团，或R1和R2，或R2和R3可选地键合形成可选取代的环状结构；R3是氢原子或可选取代的脂肪烃基团，或R3可选地键合到环A上的碳原子上形成可选取代的环状结构；环A是可选取代的苯环；环B是（i）可选取代的融合环，或（ii）具有可选取代的碳酰胺基团的吡啶环（吡啶环可进一步取代）。

  公开号：

  US20100004238A1

文献信息

• FUSED HETEROCYCLIC COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2103620A1

  公开（公告）日：2009-09-23

  The present invention provides a fused heterocyclic compound having a tyrosine kinase inhibitory action, which is represented by the formula: wherein R1 is a hydrogen atom, a halogen atom, or an optionally substituted group bonded via a carbon atom, a nitrogen atom or an oxygen atom; R2 is a hydrogen atom, or an optionally substituted group bonded via a carbon atom or a sulfur atom, or R1 and R2, or R2 and R3 are optionally bonded to each other to form an optionally substituted ring structure; R3 is a hydrogen atom or an optionally substituted aliphatic hydrocarbon group, or R3 is optionally bonded to the carbon atom on ring A to form an optionally substituted ring structure; ring A is an optionally substituted benzene ring; and ring B is (i) an optionally substituted fused ring, or (ii) a pyridine ring having optionally substituted carbamoyl (the pyridine ring is optionally further substituted).

  本发明提供了一种具有酪氨酸激酶抑制作用的融合杂环化合物，其化学式如下： 其中 R1是氢原子、卤素原子或通过碳原子、氮原子或氧原子键合的可选择取代基； R2是氢原子，或通过碳原子或硫原子键合的可选择取代基，或 R1和R2，或R2和R3可选择键合在一起形成可选择取代的环结构； R3是氢原子或可选择取代的脂肪烃基，或 R3可选择键合到环A上的碳原子上形成可选择取代的环结构； 环A是可选择取代的苯环；环B是 (i) 可选择取代的融合环，或 (ii) 具有可选择取代的氨基甲酰基的吡啶环（吡啶环可进一步取代）。
• [EN] MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS<br/>[FR] MODULATEURS DU RÉCEPTEUR X4 DE LA PROTÉINE G ASSOCIÉE À MAS ET PRODUITS ET PROCÉDÉS ASSOCIÉS
  申请人：ESCIENT PHARMACEUTICALS INC

  公开号：WO2021211839A1

  公开（公告）日：2021-10-21

  Methods are provided for modulating MRGPR X4 generally, or for treating a MRGPR X4 dependent condition more specifically, by contacting the MRGPR X4 or administering to a subject in need thereof, respectively, an effective amount of a compound having the structure of Formula (I): or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein m, n, p, t, A, B, Z, R1, R2 and R3 are as defined herein. Pharmaceutical compositions containing such compounds, as well as to compounds themselves, are also provided. The Mas-Related G-protein (MRGPR) X4 modulators, are in particular isoindolinones and isoquinolinones substituted on the carbocyclic ring. The compounds are useful to treat itch associated conditions, pain associated conditions, or an autoimmune disorder.

  提供了一种调节MRGPR X4的方法，或者更具体地用于治疗依赖于MRGPR X4的疾病，方法是通过接触MRGPR X4或向需要的受试者施用具有Formula (I)结构的化合物的有效量，或其药学上可接受的异构体、消旋体、水合物、溶剂化合物、同位素或盐，其中m、n、p、t、A、B、Z、R1、R2和R3的定义如本文所述。还提供了含有这种化合物的药物组合物，以及这些化合物本身。具体来说，Mas-Related G-protein (MRGPR) X4调节剂是在碳环上取代的异吲哚酮和异喹啉酮。这些化合物可用于治疗与瘙痒相关的疾病、与疼痛相关的疾病或自身免疫性疾病。
• [EN] MODIFIED ISOINDOLINONES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS<br/>[FR] ISOINDOLINONES MODIFIÉES EN TANT QU'INHIBITEURS DE GLUCOSYLCÉRAMIDE SYNTHASE
  申请人：MERCK SHARP & DOHME

  公开号：WO2022115301A1

  公开（公告）日：2022-06-02

  The present invention relates to compounds of Formula (I): and pharmaceutically acceptable salts or prodrug thereof. The present invention also relates to compositions comprising at least one compound of Formula (I), and methods of using the compounds of Formula (I) for treatment or prophylaxis of lysosomal storage diseases, neurodegenerative disease, cystic disease, cancer, or a diseases or disorders associated with elevated levels of glucosylceramide (GlcCer), glucosylsphingosine (GlcSph) and/or other glucosylceramide-based glycosphingolipids (GSLs).

  本发明涉及式（I）化合物及其药学上可接受的盐或前药。本发明还涉及包含至少一种式（I）化合物的组合物，以及使用式（I）化合物治疗或预防溶酶体贮积病、神经退行性疾病、囊性疾病、癌症或与葡糖鞘氨醇脂（GlcCer）、葡糖鞘氨醇（GlcSph）和/或其他葡糖鞘氨醇基糖脂（GSL）水平升高相关的疾病或障碍的方法。
• MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS
  申请人：Escient Pharmaceuticals, Inc.

  公开号：US20210340106A1

  公开（公告）日：2021-11-04

  Methods are provided for modulating MRGPR X4 generally, or for treating a MRGPR X4 dependent condition more specifically, by contacting the MRGPR X4 or administering to a subject in need thereof, respectively, an effective amount of a compound having the structure of Formula (I): or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein m, n, p, t, A, B, Z, R 1 , R 2 and R 3 are as defined herein. Pharmaceutical compositions containing such compounds, as well as to compounds themselves, are also provided.
• Design and Synthesis of Pyrrolo[3,2-<i>d</i>]pyrimidine Human Epidermal Growth Factor Receptor 2 (HER2)/Epidermal Growth Factor Receptor (EGFR) Dual Inhibitors: Exploration of Novel Back-Pocket Binders
  作者：Youichi Kawakita、Hiroshi Banno、Tomohiro Ohashi、Toshiya Tamura、Tadashi Yusa、Akiko Nakayama、Hiroshi Miki、Hidehisa Iwata、Hidenori Kamiguchi、Toshimasa Tanaka、Noriyuki Habuka、Satoshi Sogabe、Yoshikazu Ohta、Tomoyasu Ishikawa

  DOI：10.1021/jm300185p

  日期：2012.4.26

  To develop novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) kinase inhibitors, we explored pyrrolo[3,2-d]pyrimidine derivatives bearing bicyclic fused rings designed to fit the back pocket of the HER2/EGFR proteins. Among them, the 1,2-benzisothiazole (42m) ring was selected as a suitable back pocket binder because of its potent HER2/EGFR binding and cell growth inhibitory (GI) activities and pseudoirreversibility (PI) profile as well as good bioavailability (BA). Ultimately, we arrived at our preclinical candidate 51m by optimization of the N-5 side chain to improve CYP inhibition and metabolic stability profiles without a loss of potency (HER2/EGFR inhibitory activity, IC50, 0.98/2.5 nM; and GI activity BT-474 cells, GI(50), 2.0 nM). Reflecting the strong in vitro activities, 51m exhibited potent tumor regressive efficacy against both HER2- and EGFR-overexpressing tumor (4-1ST and CAL27) xenograft models in mice at oral doses of 50 mg/kg and 100 mg/kg.